1 September 2022 - The September 2022 issue of the New Zealand Pharmaceutical Schedule is now available and in effect.

There a few major new/revised listings of note this month:

• Benralizumab (Fasenra) - new medicine
• Mepolizumab (Nucala) - restriction change
• Obinutuzumab (Gazyva) - new indication

There is no entry for tixagevimab and cilgavimab (Evusheld) in either the community or hospital medicine schedule update.

Read New Zealand Pharmaceutical Schedule update